Fast-growing Duoning Biotech seeks winning formula for pricey IPO
The provider of bioprocessing services for the drugs sector has been expanding rapidly via aggressive M&A, backed by big-name investors Key Takeaways: WuXi Biologics is Duoning Biotechnology’s biggest client and…
RELATED ARTICLES
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG -
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
FAST NEWS: WuXi XDC kicks off IPO with star cornerstone investors
2269.HK
-
FAST NEWS: WuXi Biologics boosts new projects target
2269.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
